```
100.0% PROCESSED      79 ITERATIONS                          8 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1047 TO    2113
PROJECTED ANSWERS:                8 TO     329

L4            8 SEA SSS SAM L2 NOT L1

=> s l3 sss ful
FULL SEARCH INITIATED 13:29:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1415 TO ITERATE

100.0% PROCESSED    1415 ITERATIONS                      153 ANSWERS
SEARCH TIME: 00.00.04

L5          153 SEA SSS FUL L2 NOT L1

=> s l5
L6          100 L5

=> s malar?
L7        11638 MALAR?

=> s l6 and l7
L8            0 L6 AND L7

=> s antimalar?
L9         8278 ANTIMALAR?

=> s l6 and l9
L10           0 L6 AND L9

=> d his

     (FILE 'HOME' ENTERED AT 13:25:56 ON 17 JUL 2002)

     FILE 'REGISTRY' ENTERED AT 13:27:05 ON 17 JUL 2002
L1               SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045
L2               STRUCTURE UPLOADED
L3               QUE L2 NOT L1
L4             8 S L3 SSS SAM
L5           153 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 13:29:10 ON 17 JUL 2002
L6           100 S L5
L7         11638 S MALAR?
L8             0 S L6 AND L7
L9          8278 S ANTIMALAR?
L10            0 S L6 AND L9

     FILE 'CAOLD' ENTERED AT 13:31:46 ON 17 JUL 2002

=> s l5
L11          22 L5

=> d l11 1-22 bib,hitstr
```

L11 ANSWER 1 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA65:13736c CAOLD
TI piperazinoalkylphenothiazines (substituted)
PA Societe Industrielle pour la Fabrication des Antibiotiques (S.I.F.A.)
DT Patent

PATENT NO.	KIND	DATE
NL 6508319		
BE 666114		

IT **7450-91-1** **7450-92-2** **7450-99-9**
7451-00-5

RN 7450-91-1 CAOLD
CN Succinic acid, compd. with 10-[4-[4-[2-(1,3-dioxolan-2-yl)ethyl]-1-piperazinyl]butyl]phenothiazine (2:1) (8CI) (CA INDEX NAME)

CM 1

CRN 16498-56-9
CMF C25 H33 N3 O2 S



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 7450-92-2 CAOLD
CN Succinic acid, compd. with 10-[4-[4-(2-m-dioxan-2-ylethyl)-1-piperazinyl]butyl]phenothiazine (2:1) (8CI) (CA INDEX NAME)

CM 1

CRN 16498-57-0
CMF C26 H35 N3 O2 S



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 7450-99-9 CAOLD
CN 10H-Phenothiazine, 10-[4-(1-piperazinyl)butyl]- (9CI) (CA INDEX NAME)



RN 7451-00-5 CAOLD
CN Phenothiazine, 10-[4-(1-piperazinyl)butyl]-, maleate (1:2) (7CI, 8CI) (CA INDEX NAME)

CM 1

CRN 7450-99-9
CMF C20 H25 N3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L11 ANSWER 2 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA64:19902d CAOLD
TI grafting 7-8 membered lactam rings onto poly-(acryl halides)
PA Monsanto Co.
DT Patent
TI grafting 7-8 membered lactam rings onto poly-(aryl halides)
AU Black, William B.; Capps, D. B.
DT Patent

PATENT NO.	KIND	DATE
US 3243477		1966

IT **7516-85-0**
RN 7516-85-0 CAOLD
CN 10H-Phenothiazine, 10-decyl- (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA64:12666d CAOLD
TI synthesis of certain N-alkylpiperazine derivs. of phenothiazine and 2-chlorophenothiazine
AU Zawisza, Tadeusz; Machon, Z.; Kuczynski, L.
IT 95701-14-7
RN 95701-14-7 CAOLD
CN Phenothiazine, 10-[4-(1-piperazinyl)butyl]-, dihydrochloride (7CI) (CA INDEX NAME)



●2 HCl

L11 ANSWER 4 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA63:616b CAOLD
TI 10-[(aminocarbamoyl-1-piperidyl)-lower-alkyl]-phenothiazines
AU Zenitz, Bernard L.; Albro, L. P.
PA Sterling Drug Inc.
DT Patent

PATENT NO.	KIND	DATE
US 3177211		1965

IT **1903-81-7**
RN 1903-81-7 CAOLD
CN Isonipecotamide, 1-(4-phenothiazin-10-ylbutyl)- (7CI, 8CI) (CA INDEX NAME)



L11 ANSWER 5 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA61:13321h CAOLD
TI 10-aminoalkylphenothiazines
AU Izumi, Michimasa; Nakanishi, M.; Tashiro, C.
PA Yoshitomi Pharmaceutical Industries, Ltd.
DT Patent

PATENT NO.	KIND	DATE
JP 64006537		1964

IT **95701-14-7**
RN 95701-14-7 CAOLD
CN Phenothiazine, 10-[4-(1-piperazinyl)butyl]-, dihydrochloride (7CI) (CA INDEX NAME)



●2 HCl

L11 ANSWER 6 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA59:13971g CAOLD
TI phenothiazine derivs.
AU Ts'ao, Chao-Ho; Hu, C. Y.; Lu, K. S.; Cheng, T. K.; Chao, C. C.; Liang, H. T.
IT 95555-49-0
RN 95555-49-0 CAOLD
CN Ethanol, 2,2'-[(4-phenothiazin-10-ylbutyl)imino]di- (7CI) (CA INDEX NAME)



L11 ANSWER 7 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA59:11172d CAOLD
TI synthetic lubricants for high temps.
PA British Petroleum Co. Ltd.; Hunt, J. M.; Gould, P.
DT Patent

PATENT NO.	KIND	DATE
GB 933505		

IT **7516-85-0**
RN 7516-85-0 CAOLD
CN 10H-Phenothiazine, 10-decyl- (9CI) (CA INDEX NAME)



L11 ANSWER 8 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA59:640h CAOLD
TI quaternary ammonium salts of 1-carbo-lower-alkoxy-4-[(10-phenothiazinyl)-lower-alkyl]-piperazines
PA Sterling Drug Inc.
DT Patent
TI quaternary ammonium salts of 1-carbo-lower-alkoxy-4-[10-phenothiazinyl)-lower-alkyl]-piperazines
AU Zenitz, Bernard L.; Albro, L. P.
DT Patent

PATENT NO.	KIND	DATE
US 3076806		1963

IT **51144-26-4 95440-06-5 101296-14-4**
RN 51144-26-4 CAOLD
CN 10H-Phenothiazine, 10-(5-chloropentyl)- (9CI) (CA INDEX NAME)



RN 95440-06-5 CAOLD
CN 1-Piperazinecarboxylic acid, 4-(4-phenothiazin-10-ylbutyl)-, ethyl ester (7CI) (CA INDEX NAME)



RN 101296-14-4 CAOLD
CN 1-Piperazinecarboxylic acid, 4-(5-phenothiazin-10-ylpentyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

L11 ANSWER 9 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA58:10209h CAOLD
TI phenothiazine derivs.
AU Izumi, Michimasa; Nakanishi, M.
PA Yoshitomi Pharmaceutical Industries, Ltd.
DT Patent

PATENT NO.	KIND	DATE
JP 62004537		1962

IT **95701-14-7**
RN 95701-14-7 CAOLD
CN Phenothiazine, 10-[4-(1-piperazinyl)butyl]-, dihydrochloride (7CI) (CA INDEX NAME)



●2 HCl

L11 ANSWER 10 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA58:531g CAOLD
TI compds. having as basic substituent a heterocyclic ring contg. at least 1 N atom
PA Chemische Fabrik Promonta G.m.b.H.
DT Patent

PATENT NO.	KIND	DATE
PI GB 901187		
DE 1145616		

IT **95701-14-7**
RN 95701-14-7 CAOLD
CN Phenothiazine, 10-[4-(1-piperazinyl)butyl]-, dihydrochloride (7CI) (CA INDEX NAME)



●2 HCl

L11 ANSWER 11 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA55:14468e CAOLD
TI phenothiazones - (V) action of K2Cr2O7 on 3-acyloxy- and 3-methoxychlorophenothiazines
AU Bodea, Cornel; Farcasan, V.
IT **102011-48-3**
RN 102011-48-3 CAOLD
CN Phenothiazine-10-heptanoic acid, hydrazide (6CI) (CA INDEX NAME)



L11 ANSWER 12 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA55:14468a CAOLD
TI phenothiazines - (IV) attempts to develop a general synthesis of .omega.-(10-phenothiazyl)aliphatic acids
AU Cauquil, Germaine; Casadevall, A.; Casadevall, E.
IT **51144-26-4 101720-10-9 101729-85-5 102011-75-6 102157-56-2 102177-90-2 102240-96-0 102558-53-2 102597-50-2 102666-38-6**
RN 51144-26-4 CAOLD
CN 10H-Phenothiazine, 10-(5-chloropentyl)- (9CI) (CA INDEX NAME)



RN 101720-10-9 CAOLD
CN Phenothiazine-10-hexanoic acid, hydrazide (6CI) (CA INDEX NAME)



RN 101729-85-5 CAOLD
CN Phenothiazine-10-valeric acid, methyl ester (6CI) (CA INDEX NAME)



RN 102011-75-6 CAOLD
CN Malonic acid, (4-phenothiazin-10-ylbutyl)-, dihydrazide (6CI) (CA INDEX NAME)



RN 102157-56-2 CAOLD
CN Phenothiazine-10-valeric acid, isopropylidenehydrazide (6CI) (CA INDEX NAME)



RN 102177-90-2 CAOLD
CN Phenothiazine-10-hexanoic acid, methyl ester (6CI) (CA INDEX NAME)



RN 102240-96-0 CAOLD
CN Malonic acid, (5-phenothiazin-10-ylpentyl)-, dihydrazide (6CI) (CA INDEX NAME)



RN 102558-53-2 CAOLD
CN Malonic acid, (4-phenothiazin-10-ylbutyl)-, diethyl ester (6CI) (CA INDEX NAME)



RN 102597-50-2 CAOLD
CN Phenothiazine-10-heptanoic acid, ethyl ester (6CI) (CA INDEX NAME)



RN 102666-38-6 CAOLD
CN Malonic acid, (5-phenothiazin-10-ylpentyl)-, diethyl ester (6CI) (CA INDEX NAME)



L11 ANSWER 13 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA55:8438d CAOLD
TI N-phenothiazinylalkylpiperidinecarboxamides
AU Cusic, John W.; Sause, H. W.
PA Searle, G. D., & Co.
DT Patent

PATENT NO.	KIND	DATE
US 2957870		1960

IT **102477-22-5**
RN 102477-22-5 CAOLD
CN Nipecotamide, 1-(4-phenothiazin-10-ylbutyl)- (6CI) (CA INDEX NAME)



L11 ANSWER 14 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA55:3625b CAOLD
TI piperidinecarboxamide derivs.
PA Searle, G. D., & Co.
DT Patent

PATENT NO.	KIND	DATE
GB 830709		
DE 1089386		

IT **102477-22-5**
RN 102477-22-5 CAOLD
CN Nipecotamide, 1-(4-phenothiazin-10-ylbutyl)- (6CI) (CA INDEX NAME)



L11 ANSWER 15 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA54:22648a CAOLD
TI bicyclic systems based on 2,6-lutidine - (III) N-derivs. of 3,9-oxazabicyclo[3.3.1]nonane
AU Nikitskaya, E. S.; Usovskaya, V. S.; Rubtsov, M. V.
IT **119299-36-4**
RN 119299-36-4 CAOLD
CN Phenothiazine, 10-[4-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)butyl]-, hydrochloride (6CI) (CA INDEX NAME)





● HCl

L11 ANSWER 16 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA53:17154f CAOLD
TI diquaternary ammonium compds.
AU Caldwell, Albert G.
DT Patent
TI diquaternary compds.
PA Wellcome Foundation Ltd.
DT Patent

PATENT NO.	KIND	DATE
GB 811643		

IT **51144-26-4 103642-85-9 103642-86-0 104176-41-2 117099-99-7**
RN 51144-26-4 CAOLD
CN 10H-Phenothiazine, 10-(5-chloropentyl)- (9CI) (CA INDEX NAME)



RN 103642-85-9 CAOLD
CN Phenothiazine, 10-[4-[(3-morpholinopropyl)amino]butyl]-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 103642-86-0 CAOLD
CN Phenothiazine, 10-[4-[(3-morpholinopropyl)amino]butyl]- (6CI) (CA INDEX NAME)



RN 104176-41-2 CAOLD
CN Phenothiazine, 10-[5-[methyl(2-piperidinoethyl)amino]pentyl]- (6CI) (CA INDEX NAME)



RN 117099-99-7 CAOLD
CN Phenothiazine, 10-[5-[methyl(2-piperidinoethyl)amino]pentyl]-, dioxalate (6CI) (CA INDEX NAME)

CM 1

CRN 104176-41-2
CMF C25 H35 N3 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



L11 ANSWER 17 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA53:14108c CAOLD
TI prepn. of N-substituted phenothiazines in tetrahydrofuran
AU Gilman, Henry; Ranck, R. O.
IT **7516-85-0 16262-72-9**
RN 7516-85-0 CAOLD
CN 10H-Phenothiazine, 10-decyl- (9CI) (CA INDEX NAME)



RN 16262-72-9 CAOLD
CN 10H-Phenothiazine, 10-octadecyl- (9CI) (CA INDEX NAME)



L11 ANSWER 18 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA52:18502e CAOLD
TI N-[(10-phenothiazinyl)-lower alkyl]-1,5-iminocycloalkanes
AU Zenitz, Bernard L.
PA Sterling Drug Inc.
DT Patent
IT **51144-26-4 116606-57-6 116606-58-7**
119148-95-7 123885-14-3
RN 51144-26-4 CAOLD
CN 10H-Phenothiazine, 10-(5-chloropentyl)- (9CI) (CA INDEX NAME)



RN 116606-57-6 CAOLD
CN Nortropine, 8-(5-phenothiazin-10-ylpentyl)- (6CI) (CA INDEX NAME)

Relative stereochemistry.



RN 116606-58-7 CAOLD
CN Nortropine, 8-(5-phenothiazin-10-ylpentyl)-, hydrochloride (6CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 119148-95-7 CAOLD
CN Nortropine, 8-(4-phenothiazin-10-ylbutyl)- (6CI) (CA INDEX NAME)

Relative stereochemistry.



RN 123885-14-3 CAOLD
CN Nortropine, 8-(4-phenothiazin-10-ylbutyl)-, acetate (6CI) (CA INDEX NAME)

Relative stereochemistry.



L11 ANSWER 19 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA52:2093e CAOLD
TI phenothiazine derivs.
AU Horclois, Raymond J.
PA Societe des usines chimiques Rhone-Poulenc
DT Patent

PATENT NO.	KIND	DATE
GB 780193		

IT **102701-44-0 112742-66-2**
RN 102701-44-0 CAOLD
CN Phenothiazine, 10-[4-(4-ethyl-1-piperazinyl)butyl]- (6CI) (CA INDEX NAME)



RN 112742-66-2 CAOLD
CN Phenothiazine, 10-[4-(4-ethyl-1-piperazinyl)butyl]-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

L11 ANSWER 20 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA51:13199i CAOLD
TI carbutamide
AU Root, Mary A.
IT **116606-57-6 119148-95-7**
RN 116606-57-6 CAOLD
CN Nortropine, 8-(5-phenothiazin-10-ylpentyl)- (6CI) (CA INDEX NAME)

Relative stereochemistry.



RN 119148-95-7 CAOLD
CN Nortropine, 8-(4-phenothiazin-10-ylbutyl)- (6CI) (CA INDEX NAME)

Relative stereochemistry.



L11 ANSWER 21 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA51:12934b CAOLD
TI phenothiazine derivs. - (I) synthesis of 10-piperazinoalkylphenothiazines
AU Hromatka, Otto; Sauter, F.; Grass, I.
IT **4708-16-1 110151-65-0 113651-07-3**
113651-08-4
RN 4708-16-1 CAOLD
CN Phenothiazine, 10-[4-(4-methyl-1-piperazinyl)butyl]- (6CI, 8CI) (CA INDEX NAME)



RN 110151-65-0 CAOLD
CN Phenothiazine, 10-[4-(4-methyl-1-piperazinyl)butyl]-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 113651-07-3 CAOLD
CN Phenothiazine, 10-[6-(2-methyl-1-piperazinyl)hexyl]-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 113651-08-4 CAOLD
CN Phenothiazine, 10-[6-(2-methyl-1-piperazinyl)hexyl]- (6CI) (CA INDEX NAME)



L11 ANSWER 22 OF 22 CAOLD COPYRIGHT 2002 ACS
AN CA51:502a CAOLD
TI phenothiazinylalkyl sulfonates
PA Societe des usines chimiques Rhone-Poulenc
DT Patent

PATENT NO.	KIND	DATE
PI GB 741618		

IT **124144-76-9**
RN 124144-76-9 CAOLD
CN Phenothiazine-10-hexanol, p-toluenesulfonate (6CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 13:25:56 ON 17 JUL 2002)

     FILE 'REGISTRY' ENTERED AT 13:27:05 ON 17 JUL 2002
L1             SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045
L2             STRUCTURE UPLOADED
L3             QUE L2 NOT L1
L4           8 S L3 SSS SAM
L5         153 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 13:29:10 ON 17 JUL 2002
L6         100 S L5
L7       11638 S MALAR?
L8           0 S L6 AND L7
L9        8278 S ANTIMALAR?
L10          0 S L6 AND L9

     FILE 'CAOLD' ENTERED AT 13:31:46 ON 17 JUL 2002
L11         22 S L5

     FILE 'USPATFULL' ENTERED AT 13:32:35 ON 17 JUL 2002

=> s 15
L12          5 L5

=> d l12 1-5 bib,ab,hitstr
```

L12 ANSWER 1 OF 5 USPATFULL
AN 2001:191129 USPATFULL
TI Fused ring calcium channel blockers
IN Snutch, Terrance P., Vancouver, Canada
PA NeuroMed Technologies, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 6310059 B1 20011030
AI US 1999-476928 19991230 (9)
RLI Continuation-in-part of Ser. No. US 1999-401699, filed on 23 Sep 1999
Continuation-in-part of Ser. No. US 1998-107037, filed on 30 Jun 1998, now patented, Pat. No. US 6011035
DT Utility
FS GRANTED
EXNAM Primary Examiner: Henley, III, Raymond
LREP Morrison & Foerster LLP
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 724
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula ##STR1##

or salts thereof,

wherein the variable are as defined herein are useful as calcium channel blockers.

IT **349498-27-7P**
(fused-ring calcium channel blockers)
RN 349498-27-7 USPATFULL
CN 10H-Phenothiazine, 10-[6-[4-(cyclohexylmethyl)-1-piperazinyl]hexyl]- (9CI) (CA INDEX NAME)



IT **5080-57-9 349498-28-8 349498-29-9**
(fused-ring calcium channel blockers)
RN 5080-57-9 USPATFULL
CN 10H-Phenothiazine, 10-[6-(4-methyl-1-piperazinyl)hexyl]- (9CI) (CA INDEX NAME)



RN 349498-28-8 USPATFULL
CN 10H-Phenothiazine, 10-[6-[4-(3-phenyl-2-propenyl)-1-piperazinyl]hexyl]- (9CI) (CA INDEX NAME)



RN 349498-29-9 USPATFULL
CN 10H-Phenothiazine, 10-[6-[4-(phenylmethyl)-1-piperazinyl]hexyl]- (9CI) (CA INDEX NAME)



IT **134860-25-6**
(reaction; fused-ring calcium channel blockers)
RN 134860-25-6 USPATFULL
CN 10H-Phenothiazine, 10-(6-chlorohexyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 5 USPATFULL
AN 1998:115860 USPATFULL
TI Tri-and tetracyclic compounds
IN Bannwarth, Wilhelm, Upper Saddle River, NJ, United States
Gerber, Fernand, Niffer, France
Grieder, Alfred, Sissach, Switzerland
Knierzinger, Andreas, Birsfelden, Switzerland
Muller, Klaus, Munchenstein, Switzerland
Obrecht, Daniel, Basel, Switzerland
Trzeciak, Arnold, Schopfheim, Germany, Federal Republic of
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 5811548 19980922
AI US 1996-669683 19960624 (8)
RLI Division of Ser. No. US 1995-475473, filed on 7 Jun 1995, now abandoned which is a continuation of Ser. No. US 1993-106508, filed on 13 Aug 1993, now abandoned
PRAI CH 1992-2725 19920831
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Gupta, Anish
LREP Johnston, George W., Tramaloni, Dennis P., Kass, Alan P.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3792
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are described compounds of the formula ##STR1## Wherein the variables have been defined herein. The compounds are useful as research tools in the determination of biologically active peptides sequences and also potentially suitable as medicaments, some of them being useful in the prevention or control of the formation of blood platelet thrombi, and some compounds are useful as intermediates.
IT **73025-93-1**
(reaction of, in prepn. of antithrombotic peptidyl tri- and tetracyclic compds.)
RN 73025-93-1 USPATFULL
CN 10H-Phenothiazine, 10-hexyl- (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 5 USPATFULL
AN 1998:115704 USPATFULL
TI Tri- and tetracyclic compounds
IN Bannwarth, Wilhelm, Upper Saddle River, NJ, United States
Gerber, Fernand, Niffer, France
Grieder, Alfred, Sissach, Switzerland
Knierzinger, Andreas, Birsfelden, Switzerland
Muller, Klaus, Munchenstein, Switzerland
Obrecht, Daniel, Basel, Switzerland
Trzeciak, Arnold, Schopfheim, Germany, Federal Republic of
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 5811389 19980922
AI US 1996-668871 19960624 (8)
RLI Continuation of Ser. No. US 1995-475473, filed on 7 Jun 1995, now abandoned which is a continuation of Ser. No. US 1993-106508, filed on 13 Aug 1993, now abandoned
PRAI CH 1992-2725 19920831
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Gupta, Anish
LREP Johnston, George W., Tramaloni, Dennis P., Kass, Alan P.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are described compounds of the formula ##STR1## Wherein the variables have been defined herein. The compounds are useful as research tools in the determination of biologically active peptides sequences and also potentially suitable as medicaments, some of them being useful in the prevention or control of the formation of blood platelet thrombi, and some compounds are useful as intermediates.
IT **73025-93-1**
(reaction of, in prepn. of antithrombotic peptidyl tri- and tetracyclic compds.)
RN 73025-93-1 USPATFULL
CN 10H-Phenothiazine, 10-hexyl- (9CI) (CA INDEX NAME)



L12 ANSWER 4 OF 5 USPATFULL
AN 90:21548 USPATFULL
TI Dihydropyridine derivatives
IN Ashimori, Atsuyuki, Kyoto, Japan
Ono, Taizo, Kyoto, Japan
Inoue, Yoshihisa, Kyoto, Japan
Fukaya, Chikara, Osaka, Japan
Yokoyama, Kazumasa, Osaka, Japan
PA Green Cross Corporation, Osaka, Japan (non-U.S. corporation)
PI US 4910195 19900320
AI US 1987-113967 19871029 (7)
PRAI JP 1986-257673 19861029
DT Utility
FS Granted
EXNAM Primary Examiner: Fan, Jane T.
LREP Sughrue, Mion, Zinn, Macpeak & Seas
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Dihydropyridine derivatives represented by formula (I): ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.6, which may be the same or different, each represents an alkyl group, a cycloalkyl group or an alkoxyalkyl group; R.sub.4 and R.sub.5, which may be the same or different, each represents a hydrogen atom, a halogen atom, a nitro group, a halogenated alkyl group, an alkylsulfonyl group, a halogenated alkoxy group, an alkylsulfinyl group, an alkyl group, a cycloalkyl group, an alkxoy group, a cyano group, an alkoxycarbonyl group or an alkylthio group (provided that R.sub.4 and R.sub.5 are not hydrogen atoms at the same time); X represents a vinylene group or an azomethine group; A and B are each an alkylene group or an alkenylene group; R.sub.7 and R.sub.8, which may be the same or different, each represents a hydrogen atom, an alkyl group, an alkenyl group, an aralkyl group, an aryl group, or a heterocyclic group (provided that R.sub.7 and R.sub.8 may combine with the adjacent nitrogen atom to form a heterocyclic ring), and acid addition salts of the dihydropyridine derivatives of formula (I).
IT **116308-72-6P 116308-73-7P 116308-74-8P**
116308-75-9P 116308-76-0P 116308-77-1P
116308-85-1P 116329-13-6P
(prepn. of, as cardiovascular agent)
RN 116308-72-6 USPATFULL
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[6-(10H-phenothiazin-10-yl)hexyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 116308-73-7 USPATFULL
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[6-(10H-phenothiazin-10-yl)hexyl]amino]ethyl ester, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 116308-72-6
CMF C37 H42 N4 O6 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 116308-74-8 USPATFULL
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[8-(10H-phenothiazin-10-yl)octyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 116308-75-9 USPATFULL
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[8-(10H-phenothiazin-10-yl)octyl]amino]ethyl ester, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 116308-74-8
CMF C39-H46 N4 O6 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 116308-76-0 USPATFULL
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[12-(10H-phenothiazin-10-yl)dodecyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 116308-77-1 USPATFULL
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[12-(10H-phenothiazin-10-yl)dodecyl]amino]ethyl ester, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 116308-76-0
CMF C43 H54 N4 O6 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 116308-85-1 USPATFULL
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[4-(10H-phenothiazin-10-yl)butyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 116329-13-6 USPATFULL
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[4-(10H-phenothiazin-10-yl)butyl]amino]ethyl ester, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 116308-85-1
CMF C35 H38 N4 O6 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



IT **116308-80-6**
(reaction of, in prepn. of dihydropyridinedicarboxylate cardiovascular agent)
RN 116308-80-6 USPATFULL
CN Butanoic acid, 3-oxo-, 2-[methyl[4-(10H-phenothiazin-10-yl)butyl]amino]ethyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 5 USPATFULL
AN 80:52630 USPATFULL
TI Photoconductive polymer material of N-alkylphenothiazine and formaldehyde
IN Watarai, Syu, Asaka, Japan
Sawada, Kenichi, Asaka, Japan
Saida, Takeshi, Asaka, Japan
PA Fuji Photo Film Co., Ltd., Minami-ashigara, Japan (non-U.S. corporation)
PI US 4229510 19801021
AI US 1979-33630 19790426 (6)
PRAI JP 1978-49459 19780426
DT Utility
FS Granted
EXNAM Primary Examiner: Martin, Jr., Roland E.; Assistant Examiner: Goodrow, John L.
LREP Sughrue, Rothwell, Mion, Zinn and Macpeak
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A photoconductive polymer material having the following repeating unit: ##STR1## wherein R represents an alkyl group is disclosed.
IT **73025-94-2**
(electrophotog. photoconductor, properties of)
RN 73025-94-2 USPATFULL
CN Formaldehyde, polymer with 10-hexyl-10H-phenothiazine (9CI) (CA INDEX NAME)

CM 1

CRN 73025-93-1
CMF C18 H21 N S



CM 2

CRN 50-00-0
CMF C H2 O



```
=> d his

     (FILE 'HOME' ENTERED AT 13:25:56 ON 17 JUL 2002)

     FILE 'REGISTRY' ENTERED AT 13:27:05 ON 17 JUL 2002
L1                SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045
L2                STRUCTURE UPLOADED
L3                QUE L2 NOT L1
L4              8 S L3 SSS SAM
L5            153 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 13:29:10 ON 17 JUL 2002
L6            100 S L5
L7          11638 S MALAR?
L8              0 S L6 AND L7
L9           8278 S ANTIMALAR?
L10             0 S L6 AND L9

     FILE 'CAOLD' ENTERED AT 13:31:46 ON 17 JUL 2002
L11            22 S L5

     FILE 'USPATFULL' ENTERED AT 13:32:35 ON 17 JUL 2002
L12             5 S L5

     FILE 'CAPLUS' ENTERED AT 13:33:16 ON 17 JUL 2002

=> s pharm?
L13       427317 PHARM?

=> s mdr
L14         3770 MDR

=> s l5 and l14
            100 L5
L15           1 L5 AND L14

=> d l15 bib,ab,hitstr
```

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1998:49698 CAPLUS
DN 128:162631
TI The primary in vitro antitumor screening of "half-mustard type" phenothiazines
AU Wuonola, Mark A.; Palfreyman, Michael G.; Motohashi, Noboru; Kawase, Masami; Gabay, Sabit; Nacsa, Janos; Molnar, Joseph
CS SCRIPTGEN Pharmaceuticals, Inc., Medford, MA, 02155, USA
SO Anticancer Research (1997), 17(5A), 3409-3423
CODEN: ANTRD4; ISSN: 0250-7005
PB Anticancer Research
DT Journal
LA English
AB The antitumor effects of "half-mustard type" phenothiazines were studied on 57 different tumor cell lines, including leukemias, non-small lung cancer, colon, central nervous system, ovarian, renal, breast, and prostate cancer, as well as melanoma cell cultures. Alkyl-urea derivs. of phenothiazines displayed in vitro antitumor activity. The phenothiazine phthalimido derivs. (1-6) were not active on the majority of cancer cell cultures. In contrast, propylureas (9, 11) were active against some leukemia cell types. Only two compds. with the butylene [(CH2)4] linker (10, 12) were active against non-small lung cancer cells. Compds. contg. the propylene linker were less effective. On colon cancer lines, tumor cells from the central nervous system and on melanoma cells the same compds. were effective, however, having substituents at the 2-position of phenothiazine seems to be important. Surprisingly, the majority of ovarian cancer cell lines (except one type, IGROVI) and five of eight renal cancer lines were not sensitive to these phenothiazine derivs. The two butylene linked phenothiazine ureas (10, 12) had moderate antiproliferative action on two renal cancer cell lines. The prostate cancer and some breast cancer cell lines were not sensitive. Nevertheless some breast cancer cell lines were apparently sensitive to CF3-substituted phenothiazine alkylureas. On the basis of these expts. one may postulate that in the case of insensitive cells an **mdr**-gene encoded multidrug resistance efflux pump is responsible for the resistance. The selectivity or organ cell specificity of the effective phenothiazines will be targeted for improvement in further studies, in order to avoid the general cytotoxic effects of "half mustard type" phenothiazines.
IT **176657-46-8**, D 681654 **180388-70-9**, D 681648
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(the primary in vitro antitumor screening of "half-mustard type" phenothiazines)
RN 176657-46-8 CAPLUS
CN Urea, N-(2-chloroethyl)-N'-[4-(10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)



RN 180388-70-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)



```
=> s l5 and l13
           100 L5
L16          3 L5 AND L13

=> d l16 1-3 bib,ab,hitstr
```

L16 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS
AN 1999:512075 CAPLUS
DN 131:286423
TI One-pot synthesis of **pharmacologically** active diamines via rhodium-catalyzed carbonylative hydroaminomethylation of heterocyclic allylic amines
AU Rische, Thorsten; Muller, Kai-Sven; Eilbracht, Peter
CS Organische Chemie I (FB 3), Universitat Dortmund, Dortmund, D-44221, Germany
SO Tetrahedron (1999), 55(32), 9801-9816
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 131:286423
AB **Pharmacol**. active derivs. of phenothiazine, iminodibenzyl, carbazole and pyrazole are prepd. with high yields and chemoselectivity by the reaction of the corresponding N-allylic or N-methallylic compds., primary or secondary amines, carbon monoxide and hydrogen in the presence of [Rh(cod)Cl]2 as catalyst via a one pot hydroformylation-amine condensation-redn. sequence.
IT **17261-45-9P 33326-77-1P 246041-10-1P 246041-11-2P 246041-12-3P 246041-13-4P 246041-14-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(one-pot synthesis of diamines via rhodium-catalyzed carbonylative hydroaminomethylation of heterocyclic allylic amines)
RN 17261-45-9 CAPLUS
CN 10H-Phenothiazine-10-butanamine, N,N-diethyl- (9CI) (CA INDEX NAME)



RN 33326-77-1 CAPLUS
CN 10H-Phenothiazine-10-butanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 246041-10-1 CAPLUS
CN 10H-Phenothiazine, 10-[4-(4-morpholinyl)butyl]- (9CI) (CA INDEX NAME)



RN 246041-11-2 CAPLUS
CN 10H-Phenothiazine, 10-[4-(1-piperidinyl)butyl]- (9CI) (CA INDEX NAME)



RN 246041-12-3 CAPLUS
CN 10H-Phenothiazine, 10-[4-(hexahydro-1H-azepin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 246041-13-4 CAPLUS
CN 10H-Phenothiazine-10-butanamine, N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 246041-14-5 CAPLUS
CN 10H-Phenothiazine-10-butanamine, N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 106 THERE ARE 106 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
AN 1989:423083 CAPLUS
DN 111:23083
TI Alk(en)ylenediamine derivatives as intermediates for dihydropyridine derivatives
IN Ashimori, Atsuyuki; Ono, Taizo; Inoue, Yoshihisa; Fukaya, Tsutomu; Yokoyama, Kazumasa
PA Green Cross Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63290847	A2	19881128	JP 1987-127734	19870525

OS MARPAT 111:23083
AB Title diamines XANR1BNR2R3 [I; X = OH, halo, R4COCH2CO2; R1, R4 = (cyclo or alkoxy)alkyl; R2, R3 = H, alkyl, alkenyl, aralkyl, aryl, heterocyclyl or NR2R3 = heterocyclyl; or R1R2 = ring; A, B = alkylene, alkenylene], as efficient intermediates for **pharmaceutical** dihydropyridine derivs., are prepd. A prepd. Li phenothiazide soln. was reacted with 1,4-dibromobutane in a THF-HMPA mixt. and the resulting soln. was further reacted with MeHNCH2CH2OH to give 44% of the corresponding phenothiazinylbutylamino deriv. which was esterified with diketene in Et2O to give phenothiazine deriv. II.
IT **116308-80-6P 120820-21-5P 120820-22-6P**
120836-34-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclocondn. of, with methylaminocrotonate and nitrobenzaldehyde)
RN 116308-80-6 CAPLUS
CN Butanoic acid, 3-oxo-, 2-[methyl[4-(10H-phenothiazin-10-yl)butyl]amino]ethyl ester (9CI) (CA INDEX NAME)



RN 120820-21-5 CAPLUS
CN Butanoic acid, 3-oxo-, 2-[methyl[6-(10H-phenothiazin-10-yl)hexyl]amino]ethyl ester (9CI) (CA INDEX NAME)



RN 120820-22-6 CAPLUS
CN Butanoic acid, 3-oxo-, 2-[methyl[8-(10H-phenothiazin-10-yl)octyl]amino]ethyl ester (9CI) (CA INDEX NAME)



RN 120836-34-2 CAPLUS
CN Butanoic acid, 3-oxo-, 2-[methyl[12-(10H-phenothiazin-10-yl)dodecyl]amino]ethyl ester (9CI) (CA INDEX NAME)



IT **120820-24-8P 120820-25-9P 120820-26-0P 120820-27-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and esterification of, with dications)
RN 120820-24-8 CAPLUS
CN Ethanol, 2-[methyl[4-(10H-phenothiazin-10-yl)butyl]amino]- (9CI) (CA INDEX NAME)



RN 120820-25-9 CAPLUS
CN Ethanol, 2-[methyl[6-(10H-phenothiazin-10-yl)hexyl]amino]- (9CI) (CA INDEX NAME)



RN 120820-26-0 CAPLUS
CN Ethanol, 2-[methyl[8-(10H-phenothiazin-10-yl)octyl]amino]- (9CI) (CA INDEX NAME)



RN 120820-27-1 CAPLUS
CN Ethanol, 2-[methyl[12-(10H-phenothiazin-10-yl)dodecyl]amino]- (9CI) (CA INDEX NAME)



IT **116308-72-6P 116308-74-8P 116308-76-0P 116308-85-1P 120820-19-1P 120836-32-0P**

120836-33-1P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **pharmaceutical**)
RN 116308-72-6 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[6-(10H-phenothiazin-10-yl)hexyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 116308-74-8 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[8-(10H-phenothiazin-10-yl)octyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 116308-76-0 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[12-(10H-phenothiazin-10-yl)dodecyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 116308-85-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[4-(10H-phenothiazin-10-yl)butyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 120820-19-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[4-(10H-phenothiazin-10-yl)butyl]amino]ethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 116308-85-1
CMF C35 H38 N4 O6 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 120836-32-0 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[6-(10H-phenothiazin-10-yl)hexyl]amino]ethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 116308-72-6
CMF C37 H42 N4 O6 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 120836-33-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl[8-(10H-phenothiazin-10-yl)octyl]amino]ethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 116308-74-8
CMF C39 H46 N4 O6 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L16 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS
AN 1967:410226 CAPLUS
DN 67:10226
TI Preliminary **pharmacological** investigation of certain new phenothiazine derivatives
AU Boissier, Jacques R.; Dumont, Claude; Forest, Jeannine; Ratouis, Roger
CS Ecole Med., Paris, Fr.
SO Therapie (1967), 22(2), 375-82
CODEN: THERAP
DT Journal
LA French
AB Nineteen piperazine derivs. of phenothiazine (CA 66: 28740c) of the general formula I were assayed for central and autonomic nervous system activity. Compds. where A = (CH2)3, R = H, X = CHMeCHMe (II), and where A = (CH2)3, R = H, X = (CH2)3 (III) were the most toxic with max. tolerated i.p. doses of 50 mg./kg. in mice. Those where A = CH2CH2, R = H, X = (CH2)3; A = (CH2)3, R = OMe, X = CH2CH2 (IV); A = (CH2)3, R = OMe, X = (CH2)3 (V); A = (CH2)4, R = H, X = CH2CH2; and A = CH2CHMeCH2, R = H, X = (CH2)3 were the least toxic with max. tolerated doses of 200 mg./kg. Acetylcholinolytic and histaminolytic activities of the 19 derivs. were greater than that of atropine or triprolidine when assayed on the isolated guinea pig ileum. All of the compds. carrying a Pr chain had cataleptic activity when injected into rats. Compds. with a (CH2)3 group (A = (CH2)3, R = H, X = CH2CH; A = (CH2)3, R = H, X = CH2CHMe; II: A = (CH2)3, R = H, X = CMe2CMe2; III; A = (CH2)3, R = H, X = CH2CH2CHMe; A = (CH2)3, R = H, X = CHMeCH2CMe2; A = (CH2)3, R = Cl, X = CH2CH2 (VI); A = (CH2)3, R = Cl, X = CHMeCHMe (VII); A = (CH2)3, R = Cl, X = (CH2)3, (VIII); and A = (CH2)3, R = CF3, X = (CH2)3 (IX)) showed psycholeptic activity in mice. This activity was maximally increased in R-substituted compds., although the nature of the radical X did not greatly affect this activity. The psycholeptic activity of the 6 R-substituted compds. (the most active compds.) was in the following order: VIII > VI >> IX > IV >> V > VII. The activity of the most active compds. was greater than that of prochlorpemazine and thioproperazine, equal to that of chlorpromazine, and slightly lower than that of fluphenazine when all compds. were assayed at 25% of the max. tolerated dose in mice.
IT **16498-56-9 16498-57-0**
RL: BIOL (Biological study)
(nervous system response to)
RN 16498-56-9 CAPLUS
CN Phenothiazine, 10-[4-[4-[2-(1,3-dioxolan-2-yl)ethyl]-1-piperazinyl]butyl]-(8CI) (CA INDEX NAME)



RN 16498-57-0 CAPLUS
CN Phenothiazine, 10-[4-[4-(2-m-dioxan-2-ylethyl)-1-piperazinyl]butyl]- (8CI) (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   22.40     254.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -2.48      -2.48

STN INTERNATIONAL LOGOFF AT 13:35:38 ON 17 JUL 2002
```